Mounjaro® KwikPen (tirzepatide) is a state-of-the-art injectable medication that aids in weight loss. It works by mimicking the GLP-1 and GIP hormones naturally found in your gut, helping to control hunger and increase feelings of fullness. When used in combination with a reduced-calorie diet and increased physical activity, it promotes effective and sustainable weight loss.

Mounjaro® is available in pre-filled pens for easy, once-weekly injections. The pens are designed for simplicity, using very small needles that make the injection process almost painless. Mounjaro® can be injected into the abdomen, thigh, or upper arm, at any time of day, with or without food. For best results, administer the injection on the same day each week. Detailed usage instructions are provided with your first order, and our team is always available to answer any questions.

Mounjaro® (tirzepatide) is intended for individuals with a BMI over 30. It may also be prescribed for those with a BMI over 27 who have weight-related health issues such as high blood pressure, diabetes, heart disease, or high cholesterol. Mounjaro® is not recommended for weight loss in individuals with Type 2 diabetes and a BMI under 27.

Mounjaro® is one of the most effective weight loss treatments available, with users typically losing 20.9% of their body weight over 36 weeks and 25.3% over 88 weeks. In clinical studies involving individuals with type 2 diabetes on metformin, Mounjaro® was shown to be twice as effective as other treatments like Wegovy and Ozempic.

The starting dose for Mounjaro® is usually 2.5 mg, taken once weekly for the first 4 weeks. This applies whether you are beginning the treatment for the first time, transitioning from another weight loss injection, or restarting Mounjaro® after a break.

When starting Mounjaro®, your dosage will follow a stepwise plan to ensure safe and effective treatment. Adjustments to your dose should only occur after you have been on your current dose for at least 4 weeks, as directed by your doctor.

For example, you might begin with the initial dose of 2.5 mg. After 4 weeks, you could move to 5 mg, and additional increases may follow, depending on how well your body responds to the treatment. The dose is then increased every four weeks until you reach the recommended 15 mg per week.

This structured approach ensures that your body has time to adapt to each dose before moving to the next level. Our clinical team will monitor your progress to ensure the treatment is effective. Continued use of Mounjaro® requires a weight loss of approximately 5% of your initial body weight over time. Always follow your doctor's recommendations and do not make any changes to your dosage without medical advice.

The maintenance doses for Mounjaro® are as follows:
• 5 mg
• 10 mg
• 15 mg (maximum recommended dose)

The maintenance dose is the long-term dose you will use after completing the initial adjustments. The appropriate maintenance dose depends on how your body responds to the medication, and your doctor will help determine the most suitable option.
For example, if you begin at 2.5 mg, gradually increase to 5 mg, and then move to 7.5 mg but experience side effects, your doctor may suggest settling at a maintenance dose of 5 mg.

Alternatively, if you reach 10 mg without any side effects but are looking for better results, your doctor might recommend increasing to 12.5 mg and eventually to the maximum dose of 15 mg.

Your doctor will tailor the dosage to suit your individual needs and weight loss treatment goals.

Increasing the dosage of Mounjaro® (tirzepatide) is essential for improving its effectiveness in managing type 2 diabetes and promoting weight loss. Clinical studies have shown that higher doses can lead to more significant reductions in blood sugar levels and body weight. For example, in trials, up to 90% of individuals taking Mounjaro® achieved an A1C of less than 7%.

A1C is a blood test that reflects your average blood sugar levels over the past 2-3 months. It measures the percentage of haemoglobin (a protein in red blood cells that carries oxygen) coated with sugar. Lower A1C levels mean better blood sugar control, which helps reduce the risk of diabetes complications. For reference:
• Below 5.7% is normal.
• 5.7%-6.4% indicates prediabetes.
• 6.5% or higher suggests diabetes.
•
Gradually increasing the doses, a process called titration, allows your body to adjust to the medication and reduces the chance of side effects. Titration involves systematically finding the right dose that balances maximum effectiveness with minimal side effects. This careful escalation ensures the treatment is both safe and effective.
For more information, visit the Mounjaro® Official Website at https://mounjaro.lilly.com.

Note: If you have not lost at least 5% of your initial weight within 6 months of reaching your maintenance dose, your doctor may recommend discontinuing the treatment or switching to an alternative.

Clinical studies Mounjaro® Summary of Product Characteristics have shown that higher doses of Mounjaro® (tirzepatide) result in more significant weight loss. Over a 72-week period, participants receiving the maximum dose of 15 mg achieved an average weight reduction of up to 22.5% of their initial body weight.

Additionally, 96% of participants on 10 mg and 15 mg doses experienced at least a 5% weight loss, compared to 89% of participants taking the 5 mg dose during the same study.

While higher doses are generally more effective for weight loss, they must be introduced gradually through a process called titration. This method helps your body adjust to the medication, minimizing side effects and ensuring a safe transition to the most effective dose.

For more information on Mounjaro® and its dosing, consult the official resources provided by Eli Lilly (https://mounjaro.lilly.com) or the UK Medicines Information Database (https://www.medicines.org.uk/emc/product/15484/smpc#gref).